Reports of patients with COVID-19 exhibiting leukocytosis, thrombocytopenia, elevated prothrombin time and partial thromboplastin time, elevated levels of fibrinogen and D-dimer, as well as the presence of anticardiolipin IgA antibodies and anti-β2-glycoprotein IgA and IgG antibodies, indicate that the systemic response triggered by SARS-CoV-2 may induce laboratory findings consistent with Systemic Lupus Erythematosus (SLE) and/or anti-phospholipid syndrome, both frequent MS comorbidities [70,71]. The gene discussed is CD79A; the disease is myeloid sarcoma.